Oncotarget

Research Papers:

TNFAIP8 interacts with LATS1 and promotes aggressiveness through regulation of Hippo pathway in hepatocellular carcinoma

Qianze Dong _, Lin Fu, Yue Zhao, Chengyao Xie, Qingchang Li and Enhua Wang

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:15689-15703. https://doi.org/10.18632/oncotarget.14938

Metrics: PDF 1766 views  |   HTML 2106 views  |   ?  


Abstract

Qianze Dong1, Lin Fu1, Yue Zhao1, Chengyao Xie1, Qingchang Li1, Enhua Wang1

1College of Basic Medical Sciences and Department of Pathology, First Affiliated Hospital, China Medical University Shenyang, Liaoning, China

Correspondence to:

Enhua Wang, email: [email protected]

Keywords: TNFAIP8, hepatocellular carcinoma, YAP, Hippo

Received: November 02, 2016     Accepted: December 28, 2016     Published: February 01, 2017

ABSTRACT

Although TNFAIP8 overexpression has been implicated in several human cancers, its clinical significance and biological function in hepatocellular carcinoma (HCC) remains unknown. Our study demonstrated that TNFAIP8 overexpression in primary HCC samples correlated with TNM stage, recurrence, poor prognosis and served as an independent favorable prognostic factor. We further showed that TNFAIP8 upregulated cell proliferation, migration, invasion and xenograft tumor growth of HCC cells. In addition, TNFAIP8 overexpression inhibited YAP phosphorylation, increased its nuclear localization and stabilization, leading to upregulation of cyclin proteins, CTGF and cell proliferation. We also found that TNFAIP8 could interact with LATS1 and decreased its phosphorylation. Depletion of LATS1 and YAP by siRNA blocked the biological effects of TNFAIP8. Collectively, the present study provides a novel finding that TNFAIP8 promotes HCC progression through LATS1-YAP signaling pathway. TNFAIP8 may serve as a candidate biomarker for poor prognosis and a target for new therapies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14938